ATE427353T1 - Heregulin varianten - Google Patents

Heregulin varianten

Info

Publication number
ATE427353T1
ATE427353T1 AT98907337T AT98907337T ATE427353T1 AT E427353 T1 ATE427353 T1 AT E427353T1 AT 98907337 T AT98907337 T AT 98907337T AT 98907337 T AT98907337 T AT 98907337T AT E427353 T1 ATE427353 T1 AT E427353T1
Authority
AT
Austria
Prior art keywords
variants
heregulin
erbb
human
provides
Prior art date
Application number
AT98907337T
Other languages
English (en)
Inventor
Marcus Ballinger
Jennifer Jones
Wayne Fairbrother
Mark Sliwkowski
James Wells
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE427353T1 publication Critical patent/ATE427353T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT98907337T 1997-02-10 1998-02-10 Heregulin varianten ATE427353T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79905497A 1997-02-10 1997-02-10

Publications (1)

Publication Number Publication Date
ATE427353T1 true ATE427353T1 (de) 2009-04-15

Family

ID=25174936

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98907337T ATE427353T1 (de) 1997-02-10 1998-02-10 Heregulin varianten

Country Status (11)

Country Link
US (3) US6387638B1 (de)
EP (1) EP0970207B1 (de)
JP (1) JP4515542B2 (de)
AT (1) ATE427353T1 (de)
AU (1) AU732027B2 (de)
CA (1) CA2278151C (de)
DE (1) DE69840699D1 (de)
DK (1) DK0970207T3 (de)
ES (1) ES2324320T3 (de)
IL (3) IL130827A0 (de)
WO (1) WO1998035036A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
AU2003203831B2 (en) * 1998-02-04 2006-08-10 Genentech, Inc. Use of heregulin as an epithelial cell growth factor
CA2318857C (en) * 1998-02-04 2013-09-24 Genentech, Inc. Use of heregulin as an epithelial cell growth factor
WO2000035474A1 (en) * 1998-12-11 2000-06-22 Khurana Tejvir S Neurite derived growth factors for use in the treatment of muscular dystrophy
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US6825333B1 (en) * 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
US20030180714A1 (en) * 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
AU2001241839A1 (en) * 2000-02-28 2001-09-12 Decode Genetics Ehf Human schizophrenia gene
US20020165144A1 (en) * 2000-02-28 2002-11-07 Decode Genetics Ehf, Iceland Human schizophrenia gene
US7495147B2 (en) * 2000-02-28 2009-02-24 Decode Genetics Ehf. Neuregulin-1 transgenic mouse and methods of use
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
CZ303658B6 (cs) * 2001-02-01 2013-02-06 F. Hoffmann-La Roche Ag Zpusob rekombinantní produkce trypsinu
CA3081228C (en) 2001-09-10 2022-02-15 Meso Scale Technologies, Llc Assay buffer, compositions containing the same, and methods of using the same
EP1495123B1 (de) 2002-03-26 2013-10-30 Zensun (Shanghai) Science and Technology Limited Auf erbb3 beruhende verfahren und zusammensetzungen zur behandlung von neoplasmen
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
AU2003237367A1 (en) * 2002-06-03 2003-12-19 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
US20040157770A1 (en) * 2003-02-10 2004-08-12 The United States Of America As Represented By The Department Of Veterans Affairs Method of inhibiting angiogenesis and neuroblastoma growth with alpha and beta isoforms of neu differentiation factor (NDF alpha and NDF beta)
SI1613350T1 (sl) 2003-04-09 2009-08-31 Genentech Inc Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa
US20060281093A1 (en) * 2003-08-05 2006-12-14 Richard Kim Erbb receptor methods and kits for monitoring chemotherapy resistance
KR100767583B1 (ko) * 2003-12-29 2007-10-17 엘지.필립스 엘시디 주식회사 액정표시장치 구동회로
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
KR100765496B1 (ko) 2005-12-09 2007-10-10 경희대학교 산학협력단 히레귤린 베타1의 ｅｇｆ-성 도메인 펩타이드를 암호화하는ｄｎａ 서열을 포함하는 재조합 아데노바이러스 및 이를포함하는 신경세포 분화 및 재생용 약학 조성물
RU2457854C2 (ru) * 2005-12-30 2012-08-10 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед Длительное высвобождение нейрегулина для улучшения сердечной функции
SG10202109176RA (en) 2006-02-23 2021-09-29 Viacyte Inc Compositions and methods useful for culturing differentiable cells
US20100215722A1 (en) * 2006-02-28 2010-08-26 Vishal Bhasin Tissue Regeneration II
EP2389951A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
WO2007113366A1 (es) * 2006-04-05 2007-10-11 Consejo Superior De Investigaciones Científicas Uso de compuestos inductores del desarrollo axonal de neuronas, composiciones terapéuticas que los contienen y sus aplicaciones
WO2008112988A2 (en) 2007-03-14 2008-09-18 Novartis Ag Apcdd1 inhibitors for treating, diagnosing or detecting cancer
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (de) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
WO2010033249A2 (en) 2008-09-22 2010-03-25 Massachusetts Institute Of Technology Compositions of and methods using ligand dimers
NZ592622A (en) 2008-11-04 2012-10-26 Viacyte Inc Stem cell aggregate suspension compositions and methods for differentiation thereof
JP5743898B2 (ja) * 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
CN103118698A (zh) * 2010-05-28 2013-05-22 意识-Nrg公司 神经调节素同种型，神经调节素多肽和其使用
EP2621532A1 (de) * 2010-09-30 2013-08-07 Merck Sharp & Dohme Corp. Erzeugung, kennzeichnung und verwendungen von anti-her3-antikörpern
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CA2881582A1 (en) 2012-08-03 2014-02-06 Cedars-Sinai Medical Center Isolating traffic-enhancing mutants of drug delivery protein
AU2013248265B2 (en) 2012-11-08 2018-11-01 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
BR112015029293A2 (pt) 2013-05-22 2018-04-24 Zensun Shanghai Science & Tech Ltd método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
ITUB20160828A1 (it) * 2016-02-18 2017-08-18 Univ Degli Studi Genova Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro
WO2020086667A1 (en) 2018-10-25 2020-04-30 American University Method for promoting adipocyte differentiation and obesity-related disease treatment
CA3222782A1 (en) * 2021-06-10 2022-12-15 Amgen Inc. Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0444961A1 (de) 1990-03-02 1991-09-04 Bristol-Myers Squibb Company Her3: Ein neues EGF-Rezeptor Homologes
AU1298392A (en) 1991-03-17 1992-09-24 Yeda Research And Development Co. Ltd. Stimulating factor of the neu receptor
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
GB9107566D0 (en) 1991-04-10 1991-05-29 Ludwig Inst Cancer Res Glial mitogenic factors,their preparation and use
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5367060A (en) 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
MX9302475A (es) 1992-04-29 1994-05-31 Amgen Inc Polipeptido de origen no natural que tiene la actividad del factor recombinante de estimulacion del receptor neu y proceso para la produccion del mis mo.
GB9217316D0 (en) 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
AU681095B2 (en) 1992-09-29 1997-08-21 President And Fellows Of Harvard College Trophic factor having ion channel-inducing activity in neuronal cells
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
WO1994028133A1 (en) 1993-05-21 1994-12-08 Amgen Inc. Recombinant neu differentiation factors
US5670342A (en) * 1995-04-06 1997-09-23 Amgen Inc. NDF peptides
US6033660A (en) * 1995-05-10 2000-03-07 Genentech, Inc. Method of treating a nervous system injury with cultured schwann cells
CA2217020A1 (en) * 1995-05-16 1996-11-21 Bristol-Myers Squibb Company Recombinant heregulins and their biological functions upon receptor activation

Also Published As

Publication number Publication date
IL130827A0 (en) 2001-01-28
ES2324320T3 (es) 2009-08-04
US20060183194A1 (en) 2006-08-17
IL174786A (en) 2011-12-29
DE69840699D1 (de) 2009-05-14
US7563583B2 (en) 2009-07-21
US7063961B2 (en) 2006-06-20
IL174786A0 (en) 2006-08-20
CA2278151C (en) 2010-11-16
JP2001521376A (ja) 2001-11-06
JP4515542B2 (ja) 2010-08-04
US6387638B1 (en) 2002-05-14
CA2278151A1 (en) 1998-08-13
EP0970207B1 (de) 2009-04-01
AU732027B2 (en) 2001-04-12
AU6317698A (en) 1998-08-26
WO1998035036A1 (en) 1998-08-13
DK0970207T3 (da) 2009-07-13
IL130827A (en) 2007-08-19
US20030129688A1 (en) 2003-07-10
EP0970207A1 (de) 2000-01-12

Similar Documents

Publication Publication Date Title
DK0970207T3 (da) Heregulin-varianter
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
DE60028970D1 (de) An her2 bindende peptidverbindungen
MXPA03010747A (es) Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
PT910647E (pt) Variantes hiperactivas da dnase i humana
CY1112101T1 (el) Νευροτροφικοι παραγοντες
EP1141286A4 (de) Cytokinrezeptor-kette
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
WO2004085461A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
DK0811068T3 (da) Humane DNase I varianter
HK1150627A1 (en) Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof
IL161296A0 (en) Glycosylphosphatidylinositol containing polypeptides
WO2001014415A3 (en) Egfh2 genes and gene products
MX9706429A (es) Variantes de dnasa i humana.
AU2001267433A1 (en) Nucleic acid molecules encoding a protein interacting with ser/thr kinase akt

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0970207

Country of ref document: EP